Hormonal
Semaglutide 2.4 mg administered subcutaneously once weekly, used as an adjunct to lifestyle interventions, produces clinically significant weight loss in adults with obesity or overweight, with efficacy superior to the previously approved GLP-1 receptor agonist liraglutide.
If you have obesity or overweight and have struggled to lose weight with diet and exercise alone, adding semaglutide 2.4 mg (a once-weekly injection) to your lifestyle changes can lead to significantly greater weight loss than lifestyle changes alone. This medication works by mimicking a hormone that reduces hunger and increases fullness. It is most effective when combined with a modest calorie deficit and regular physical activity. Previous medications may not be as effective, and this treatment offers a more durable solution for weight management, including maintenance over time.
greater WL was observed with semaglutide than liraglutide (21)... patients experienced a mean WL at week 52 from baseline of –13.8% compared with –7.8% for liraglutide 3.0 mg and –2.3% for placebo (21).
Why this rating
The paper describes five large-scale, randomized, double-blind, placebo-controlled Phase 3 clinical trials (STEP 1-5) involving approximately 5,000 participants, representing high-quality clinical evidence.
Source
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
Robert F. Kushner et al. · Obesity · 2020
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →